Efficacy and toxicity of factor Xa inhibitors

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 16, Issue 1, 2013, Pages 74-88

  Bondarenko, Maryna ^a   Curti, Christophe ^b,c   Montana, Marc ^c   Rathelot, Pascal ^b,c   Vanelle, Patrice ^b,c  

^a HÔPITAL NORD   (France)

^b AIX MARSEILLE UNIV   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; APIXABAN; BETRIXABAN; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DABIGATRAN; DABIGATRAN ETEXILATE; DAREXABAN; EDOXABAN; ELIQUI; ENOXAPARIN; EPTIFIBATIDE; ERIBAXABAN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HEPARIN DERIVATIVE; LETAXABAN; LOW MOLECULAR WEIGHT HEPARIN; N [2 [4 (1 METHYL 4 PIPERIDINYL) 1 PIPERAZINYL] 2 OXO 1 PHENYLETHYL] 1H INDOLE 6 CARBOXAMIDE; OTAMIXABAN; PLACEBO; RIVAROXABAN; UNCLASSIFIED DRUG; WARFARIN; XARELT;

ACUTE CORONARY SYNDROME; ARTICLE; BLEEDING; BLOOD CLOTTING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CEREBROVASCULAR ACCIDENT; DRUG CONTRAINDICATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; OPTIMAL DRUG DOSE; ORTHOPEDIC SURGERY; RECOMMENDED DRUG DOSE; RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; SYSTEMIC DISEASE; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

EID: 84874393418     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J33P49     Document Type: Article

References (65)

1. Amin A, Stemkowski S, Lin J, et al. Thromboprophylaxis rates in US medical centers: success or failure? J Thromb Haemost, 2007; 5(8):1610-1616.
2. Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost, 2007; 98(4):756-764.
3. Société Française d'Anesthésie et de Réanimation (SFAR). Prévention de la maladie thromboembolique veineuse périopératoire et obstétricale - Recommandations pour la pratique clinique 2005.
4. Bereznicki LR, Peterson GM. New antithrombotics for atrial fibrillation. Cardiovasc Ther, 2010; 28(5):278-286.
5. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA, 2001; 285(18):2370-2375.
6. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm, 2007; 13(6):475-486.
7. Baser O. Prevalence and economic burden of venous thromboembolism after total hip arthroplasty or total knee arthroplast. Am J Manag Care, 2011; 17:S6-S8.
8. Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest, 2008; 133(6 Suppl):381S-453S.
9. Kearon C, Kahn SR, Agnelli G, et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008; 133(6 Suppl):454S-545S.
10. Agence française de sécurité sanitaire des produits de santé (Afssaps). Prévention et traitement de la maladie thrombo-embolique veineuse en médecine. Recommandations de bonne pratique 2009.
11. Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008; 133(6 Suppl):141S-159S.
12. Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest, 2008; 133(6 Suppl):160S-198S.
13. Weitz JI, Hirsh J, Samama MM, et al. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008; 133(6 Suppl):234S-256S.
14. Bertoletti L, Mismetti P. Les nouveaux anticoagulants dans la maladie thromboembolique veineuse. Rev Mal Respir, 2011; 28(8):1008-1016.
15. Lassen MR, Laux V. Emergence of new oral antithrombotics: a critical appraisal of their clinical potential. Vasc Health Risk Manag, 2008; 4(6):1373-1386.
16. Steffel J, Braunwald E. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism. Eur Heart J, 2011; 32(16):1968-1976.
17. Lip GYH, Larsen TB, Skjoth F, et al. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol, 2012; 60(8):738-746.
18. Mantha S, Ansell F. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation. Thromb Haemost, 2012; 108(3):476-484.
19. Harenberg J, Marx S, Diener HC, et al. Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis. Int Angiol, 2012; 31(4):330-339.
20. Kansal AR, Sharma M, Bradley-Kennedy C, et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Thromb Haemost, 2012; 108(4):672-682.
21. Schneeweiss S, Gagne JJ, Patrick AR, et al. Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes, 2012; 5(4):480-486.
22. Tsiara S, Pappas K, Boutsis D, et al. New oral anticoagulants: should they replace heparins and warfarin? Hellenic J Cardiol, 2011; 52(1):52-67.
23. Perzborn E. Factor Xa inhibitors - new anticoagulants for secondary haemostasis. Hamostaseologie, 2009; 29(3):260-267.
24. European Medicines Agency. Summary of product characteristics - rivaroxaban (Xarelto®) 2008. Available at http://www.ema.europa.eu.
25. Haute Autorité de Santé. Avis de la Commission de Transparence - Xarelto® 2009. Available at http://www.hassante.fr/portail/upload/docs/application/pdf/2009-02/xarelto_-_ct-6017.pdf.
26. Rosencher N, Arnaout L, Chabbouh T, et al. Rivaroxaban (Xarelto®): efficacité et tolérance. Ann Fr Anesth Reanim, 2008 Dec; 27(Suppl 3):S22-S27.
27. Agnelli G, Gallus A, Goldhaber SZ, et al. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. Circulation, 2007; 116(2):180-187.
28. Buller HR, Lensing AW, Prins MH, et al. A doseranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein- DVT Dose-Ranging Study. Blood, 2008; 112(6):2242-2247.
29. Mismetti P, Laporte S. Rivaroxaban: données pharmaco-cliniques. Ann Fr Anesth Reanim, 2008; 27(Suppl 3):S16-S21.
30. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med, 2010; 363(26):2499-2510.
31. The EINSTEIN-PE Investigators, Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med, 2012; 366:1287-1297.
32. Romualdi E, Donadini MP, Ageno W. Oral rivaroxaban after symptomatic venous thromboembolism: the continued treatment study (EINSTEIN-extension study). Expert Rev Cardiovasc Ther, 2011; 9(7):841-844.
33. Singer DE, Albers GW, Dalen JE, et al. Antithrombotic therapy in atrial fibrillation, American College of Chest Physicians Evidence- Based Clinical Practice Guidelines (8th Edition). Chest, 2008; 133:546S-592S.
34. Fuster V, Rydén LE, Cannom DS, et al. 2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. J Am Coll Cardiol, 2011; 57(11):e101-e198.
35. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in non-valvular atrial fibrillation. N Engl J Med, 2011; 365(10):883-891.
36. Haute Autorité de Santé. Avis de la Commission de Transparence - Xarelto® 2012. Available at http://www.hassante.fr/portail/upload/docs/application/pdf/2012-04/xarelto_avc_14032012_avis_ct11771.pdf.
37. Mega JL, Braunwald E, Mohanavelu S, et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI 46): a randomised, double-blind, phase II trial. Lancet, 2009; 374(9683):29-38.
38. European Medicines Agency. Summary of product characteristics - apixaban (Eliquis®) 2011. Available at http://www.ema.europa.eu.
39. Haute Autorité de Santé. Avis de la Commission de Transparence - Eliquis® 2012. Available at http://www.hassante.fr/portail/upload/docs/application/pdf/2012-02/eliquis_18012012_avis_ct11097.pdf.
40. Buller H, Deitchman D, Prins M, et al. Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost, 2008; 6(8):1313-1318.
41. Agnelli G, Buller HR, Cohen A, et al. Apixaban for Extended Treatment of venous thromboembolism N Engl J Med, 2012; DOI: 10.1056/NEJMoa1207541.
42. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 2011; 365(11):981-992.
43. Connolly SJ, Eikelboom JC. Apixaban in patients with atrial fibrillation. N Engl J Med, 2011; 364:806-817.
44. Alexander JH, Lopes RD, James S, et al. Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med, 2011; 365:699-708.
45. Turpie AG, Bauer KA, Davidson BL, et al. A randomized evaluation of betrixaban, an oral factor Xa inhibitor, for prevention of thromboembolic events after total knee replacement (EXPERT). Thromb Haemost, 2009; 101(1):68-76.
46. Gras J. Edoxaban for the prevention of thromboembolic events after surgery. Drugs Today (Barc), 2011; 47(10):753-761.
47. Ruff CT, Giugliano RP, Antman EM, et al. Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial Infarction study 48 (ENGAGE AFTIMI 48). Am Heart J, 2010; 160(4):635-641.
48. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost, 2010; 104(3):633-641.
49. Eriksson BI, Turpie AG, Lassen MR, et al. A dose escalation study of YM150, an oral direct factor Xa inhibitor, in the prevention of venous thromboembolism in elective primary hip replacement surgery. J Thromb Haemost, 2007; 5(8):1660-1665.
50. Fuji T, Nakamura M, Takeuchi M. Darexaban for the prevention of venous thromboembolism in Asian patients undergoing orthopedic surgery: results from 2 randomized, placebo-controlled, double-blind studies. Clin Appl Thromb Hemost. 2012; doi: 10.1177/1076029612457810.
51. Eriksson BI, Turpie AG, Lassen MR, et al. Prevention of venous thromboembolism with an oral factor Xa inhibitor, YM150, after total hip arthroplasty. A dose finding study (ONYX-2). J Thromb Haemost, 2010; 8:714-721.
52. Lip GYH, Halperin JL, Petersen P, Rodgers GM, Renfurm RW. Safety and tolerability of the oral Factor Xa inhibitor, YM150 versus warfarin in 1297 patients with non-valvular atrial fibrillation: a dose confirmation study (OPAL-2). (Abstract OTH- 083) J Thromb Haemost, 2011;9(Suppl 2):748. 53.
53. Turpie AGG, Lip GYH, Minematsu K, Goto S, Renfurm RW, Wong KSL. Safety and tolerability of YM150 in subjects with non-valvular atrial fibrillation: a phase II study. (Abstract 1194) Eur Heart J, 2010;31(Abstr. Supp.):173.
54. Steg PG, Mehta SR, Jukema JW, et al. RUBY-1: a randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J, 2011; 32:2541-2554.
55. Weitz JI, Cao C, Eriksson BI, et al. A dose-finding study with TAK-442, an oral factor Xa inhibitor, in patients undergoing elective total knee replacement surgery. Thromb Haemost, 2010; 104(6):1150-1157.
56. Agnelli G, Haas S, Ginsberg JS, et al. A phase II study of the oral factor Xa inhibitor LY517717 for the prevention of venous thromboembolism after hip or knee replacement. J Thromb Haemost, 2007; 5(4):746-753.
57. Cohen M, Bhatt DL, Alexander JH, et al. Randomized, double-blind, dose-ranging study of otamixaban, a novel, parenteral, short-acting direct factor Xa inhibitor, in percutaneous coronary intervention: the SEPIA-PCI trial. Circulation, 2007; 115(20):2642-2651.
58. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 2007; 116:e148-e304.
59. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non- ST-segment elevation acute coronary syndromes. The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology. Eur Heart J, 2007; 28:1598-1660.
60. Hamm CW, Bassand JP, Agewall S, et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2011; 32(23):2999-3054.
61. Sabatine MS, Antman ES, Widimsky P, et al. Otamixaban for the treatment of patients with non-ST-elevation acute coronary syndromes (SEPIAACS1 TIMI 42): a randomised, double-blind, active-controlled, phase 2 trial. Lancet, 2009; 374:787-795.
62. Watkins PB, Desai M, Berkowitz SD, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf, 2011; 34(3): 243-252.
63. Ageno W, Gallus AS, Wittkowsky A, et al. Oral anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (9th Edition). Chest, 2012; 141(2 Suppl):e44S-88S.
64. Ruff CT, Giugliano RP. Novel Oral Antithrombotic Therapies for Patients With Atrial Fibrillation. The American Journal of Cardiology. Available at http://elsevierocme.com/wpcontent/uploads/2010/09/930009_Afib-AJCUpdate.pdf.
65. Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J, 2012; 163(6):931-937.